![]() |
市場調査レポート
人工呼吸器関連肺炎(VAP): パイプライン分析Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019 |
||||||
発行 | Global Markets Direct | 商品コード | 264097 | ||||
出版日 | ページ情報 | 英文 147 Pages ![]() |
|||||
価格 |
|
人工呼吸器関連肺炎(VAP): パイプライン分析 Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019 | ||
出版日: 2019年02月01日 | ページ情報: 英文 147 Pages |
|
人工呼吸器関連肺炎(VAP)は、気管チューブまたは気管開口による人工呼吸器装着後48時間以降に発症する肺炎で、下気道や肺質への微生物侵入が原因です。最も重要な兆候は熱、低体温、膿性痰、低酸素血です。
当レポートでは、人工呼吸器関連肺炎(VAP)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 4, 8, 8, 1 and 1 respectively.
Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.